Arterra Bioscience
ARBS.MI · MIL
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.39 | -0.43 | 0.43 | 0.00 |
| FCF Yield | 3.06% | 8.53% | 9.01% | 4.08% |
| EV / EBITDA | 4.93 | 4.20 | 4.48 | 8.55 |
| Quality | ||||
| ROIC | 9.10% | -2.50% | 2.48% | 15.06% |
| Gross Margin | 87.46% | 55.46% | 13.72% | 14.19% |
| Cash Conversion Ratio | 0.80 | 0.95 | 0.99 | 1.26 |
| Growth | ||||
| Revenue 3-Year CAGR | 5.13% | -11.06% | 8.37% | 20.52% |
| Free Cash Flow Growth | -57.65% | -27.25% | 64.56% | 709.72% |
| Safety | ||||
| Net Debt / EBITDA | -1.46 | -1.79 | -1.67 | -2.38 |
| Interest Coverage | 1,075.94 | -35.56 | 48.60 | 235.30 |
| Efficiency | ||||
| Inventory Turnover | 0.39 | 1.10 | 2.65 | 6.46 |
| Cash Conversion Cycle | 1,018.32 | 490.96 | 385.31 | 273.00 |